XNAS · EPRX
-0.14% · -$0.0100 · Vol 179.1K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals Inc. Common Stock

$6.91
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is EPRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for EPRX are being assembled.
About Eupraxia Pharmaceuticals Inc. Common Stock
Listed since
2021
Employees
49
Country
US

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$7.01
Day high
$7.11
Day low
$6.80
Previous close
$6.92
52W high
$7.11
-2.81% from high
52W low
$5.92
83% of range
Market cap
$452.1M
Shares out
65.3M
Volume
179.1K
VWAP
$6.92
Price history computed in-house
1W
+7.30%
1M
+15.55%
SMA 50 $6.45 · above
SMA 200 $6.45 · above
52W position 83%
Veridion warehouse edge

Warehouse intelligence for EPRX.

Veridion Score
43
0: 641: 402: 503: 104: 825: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

EPRX insider activity

Eupraxia Pharmaceuticals Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for EPRX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

EPRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EPRX in this window.
Lobbying spend

EPRX lobbying filings, year to date.

Registered lobbying filings matched to Eupraxia Pharmaceuticals Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EPRX in this window.
Latest news · EPRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for EPRX.
Options
Sovereign unlock shows live options positioning for EPRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.